ADOCY (Adocia) Other Financing: $-0.00 Mil (TTM As of Dec. 2025)


ADOCY Adocia ADOCY
29 GF Score
Price $11.80
GF Value $2.54
! 7 Warning Signs
View Full Analysis

What is Adocia Other Financing?

Adocia ADOCY 29 Other Financing is $-0.00 Mil as of Dec. 2025. GuruFocus rates ADOCY with a GF Score™ of 29/100 and a GF Value™ of $2.54. The stock has 7 warning signs investors should review.

Adocia's Other Financing for the six months ended in Dec. 2025 was $-0.00 Mil.

Adocia's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.00 Mil.

Adocia Other Financing Historical Data

* Premium members only.

The historical data trend for Adocia's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adocia Other Financing Chart

Adocia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Adocia Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.58 -0.00 -0.00 0.00 -0.00
ADOCY
29GF Score
Adocia ADOCY
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adocia Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-0.00 Mil mean?
Adocia (ADOCY) has a Other Financing of $-0.00 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Adocia and its competitors.
Is Adocia's Other Financing too high?
Adocia's current Other Financing is $-0.00 Mil. Overall, Adocia has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Adocia's Other Financing compare to VRTX and REGN?
Adocia's Other Financing of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Adocia and its competitors. Adocia's current Other Financing is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adocia stock overvalued right now?
Adocia (ADOCY) has a current Other Financing of $-0.00 Mil. The stock's GF Value™ is $2.54, compared to a current price of $11.80 — trading 364.6% above its estimated fair value. The current Other Financing is $-0.00 Mil. Adocia's overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Adocia (ADOCY), the current Other Financing is $-0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adocia (ADOCY) Overvalued in 2026?

Based on GuruFocus' analysis, Adocia stock appears to be overvalued. The current stock price of $11.80 is trading 364.6% above its estimated GF Value™ of $2.54.

Key valuation signals for ADOCY:

  • Other Financing: $-0.00 Mil
  • GF Value™: $2.54 vs. price of $11.80 (364.6% above fair value)
  • GF Score™: 29/100 with 7 warning signs

No single metric tells the full story. See the ADOCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adocia Business Description

Address 115 Avenue Lacassagne, Lyon, FRA, 69003
Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.
29GF Score

Get the complete analysis for ADOCY

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.80
Price
$2.54
GF Value